nitrendipine has been researched along with Kidney Failure, Chronic in 31 studies
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The goal of the present studies was to determine whether calcium channel blockade may alter hemodialysis-related leukotriene B4 (LTB4) generation and neutropenia in 12 patients with end-stage renal failure." | 9.07 | Hemodialysis-related leukotriene B4 generation and neutropenia during calcium channel blockade. ( Schiffl, H; Strasser, T, 1991) |
| " The pharmacokinetics, bioavailability, metabolism and antihypertensive effects of nitrendipine have been studied in 12 patients with impaired renal function and moderate to severe hypertension." | 7.68 | Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension. ( Eichelbaum, M; Fischer, C; Kuhlmann, U; Machleidt, C; Mast, V; Mikus, G, 1991) |
| "In 11 hypertensive patients with chronic renal failure we studied the short-term effects of the calcium antagonist nitrendipine, the angiotensin-converting enzyme inhibitor cilazapril, and the combination of both drugs on blood pressure, renal hemodynamics, and proteinuria in a randomized, double-blind, placebo-controlled way." | 6.67 | Effects of nitrendipine and cilazapril on renal hemodynamics and albuminuria in hypertensive patients with chronic renal failure. ( Huysmans, FT; Kleinbloesem, CH; Kloke, HJ; Koene, RA; van Hamersvelt, HW; Wetzels, JF, 1990) |
| " The goal of the present studies was to determine whether calcium channel blockade may alter hemodialysis-related leukotriene B4 (LTB4) generation and neutropenia in 12 patients with end-stage renal failure." | 5.07 | Hemodialysis-related leukotriene B4 generation and neutropenia during calcium channel blockade. ( Schiffl, H; Strasser, T, 1991) |
| "The relationship between the presence of arterial calcinosis and the antihypertensive response to calcium blockers was studied in 40 hypertensive patients with end-stage renal failure (ESRF) on chronic hemodialysis, before and during 16 weeks after administration of nitrendipine in monotherapy." | 5.07 | Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. ( Boussac, I; Delavaux, G; Guerin, AP; London, GM; Marchais, SJ; Metivier, F, 1991) |
| "The relationship between the presence of arterial calcinosis and the antihypertensive response to calcium blockers was studied in 40 hypertensive patients with end-stage renal failure (ESRF) on chronic hemodialysis, before and during 16 weeks after administration of nitrendipine in monotherapy." | 5.07 | Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. ( Boussac, I; Delavaux, G; Guerin, AP; London, GM; Marchais, SJ; Metivier, F, 1991) |
| "To investigate the pathogenetic constellation and its modification by calcium channel blockade in hypertension associated with chronic nonoliguric renal failure, blood pressure (BP), various pressor factors or correlates, cardiovascular responsiveness, and plasma atrial natriuretic peptide (ANP) were assessed in 15 hypertensive patients (serum creatinine 160-715 mumol/l) before and after 6 weeks of intervention with the agent nitrendipine." | 5.06 | Hypertensive dysregulation and its modification by calcium channel blockade in nonoliguric renal failure. ( Bürgisser, E; Ferrier, C; Gnädinger, MP; Jahn, H; Schohn, D; Weidmann, P, 1989) |
| "To evaluate the potential therapeutic value of calcium antagonists in hypertension associated with impaired renal function, blood pressure (BP), certain regulatory factors, and metabolic correlates of cardiovascular risk have been assessed in 15 patients with mild to marked chronic renal failure before and after 6 weeks of therapy with nitrendipine." | 5.06 | Antihypertensive and hypouricaemic effects of nitrendipine in chronic renal failure. ( Gnädinger, MP; Jahn, H; Riesen, W; Schohn, D; Weidmann, P, 1989) |
| " The pharmacokinetics, bioavailability, metabolism and antihypertensive effects of nitrendipine have been studied in 12 patients with impaired renal function and moderate to severe hypertension." | 3.68 | Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension. ( Eichelbaum, M; Fischer, C; Kuhlmann, U; Machleidt, C; Mast, V; Mikus, G, 1991) |
| "Systemic hypertension often accompanies chronic renal failure and can accelerate its progression to end-stage renal disease (ESRD)." | 2.73 | Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis. ( Baum, D; Greiner, W; Littlewood, KJ; Zoellner, Y, 2007) |
| "Aortic stiffness and left ventricular hypertrophy (LVH) are predictors of mortality in hemodialysis (HD) patients." | 2.71 | Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. ( Adda, H; Guerin, AP; London, GM; Marchais, SJ; Metivier, F; Pannier, B, 2003) |
| "In a double-blind study, 24 ESRD patients with LVH were randomized to 12 months' administration of either the angiotensin-converting enzyme (ACE) inhibitor perindopril (n = 14) or the calcium channel blocker nitrendipine (n = 10)." | 2.67 | Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. ( Cuche, JL; Guerin, AP; London, GM; Marchais, SJ; Pannier, B; Safar, ME, 1994) |
| "In 11 hypertensive patients with chronic renal failure we studied the short-term effects of the calcium antagonist nitrendipine, the angiotensin-converting enzyme inhibitor cilazapril, and the combination of both drugs on blood pressure, renal hemodynamics, and proteinuria in a randomized, double-blind, placebo-controlled way." | 2.67 | Effects of nitrendipine and cilazapril on renal hemodynamics and albuminuria in hypertensive patients with chronic renal failure. ( Huysmans, FT; Kleinbloesem, CH; Kloke, HJ; Koene, RA; van Hamersvelt, HW; Wetzels, JF, 1990) |
| " The aim of the study was to investigate the influence of kidney function and/or dialysis treatment on the pharmacokinetic and pharmacodynamic profile of a solution of nitrendipine and to assess its antihypertensive efficacy." | 1.29 | Pharmacodynamics and pharmacokinetics of oral nitrendipine solution in hypertensive patients with advanced renal failure. ( Blanke, PM; Gellert, J; Heintz, B; Kierdorf, H; Kindler, J; Müller, A; Rämsch, KD; Wargenau, M, 1993) |
| " The observed doubling of the half-lives and the increases in Cmax did not reach significance because of the large variability in each group." | 1.28 | Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function. ( Ankermann, T; Breimer, DD; Kirch, W; Soons, PA, 1992) |
| "Nitrendipine was as highly bound to plasma proteins in patients with renal failure, as in subjects with normal renal function." | 1.28 | Pharmacokinetics of nitrendipine in terminal renal failure. ( Böhm, R; Mooy, J; Rahn, KH; Schiffers, P; van Bortel, L, 1989) |
| " A compartment-independent pharmacokinetic analysis showed no difference in the absorption, elimination, or metabolism of nitrendipine between subjects with normal renal function and those with impaired renal function." | 1.27 | Pharmacokinetics of nitrendipine in patients with renal failure: comparison to normal subjects. ( Aronoff, GR, 1984) |
| "Enalapril treatment (5 mg/kg/day, n = 11) or felodipine (30 mg/kg/day, n = 11) reduced systolic blood pressure to a comparable degree." | 1.27 | Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat. ( Cubela, R; Debrevi, L; Jackson, B; Johnston, CI; Whitty, M, 1987) |
| "Nitrendipine was very well tolerated, and no side effects were observed." | 1.27 | Nitrendipine in patients with end-stage renal disease and hypertension. ( Bambauer, R; Jutzler, GA; Keller, HE; Walter, R; Weber, U, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (38.71) | 18.7374 |
| 1990's | 15 (48.39) | 18.2507 |
| 2000's | 4 (12.90) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| London, GM | 4 |
| Marchais, SJ | 4 |
| Guerin, AP | 4 |
| Metivier, F | 3 |
| Adda, H | 1 |
| Pannier, B | 2 |
| Morrone, LF | 1 |
| Ramunni, A | 1 |
| Fassianos, E | 1 |
| Saracino, A | 1 |
| Coratelli, P | 1 |
| Passavanti, G | 1 |
| Vonend, O | 1 |
| Marsalek, P | 1 |
| Russ, H | 1 |
| Wulkow, R | 1 |
| Oberhauser, V | 1 |
| Rump, LC | 1 |
| Littlewood, KJ | 1 |
| Greiner, W | 1 |
| Baum, D | 1 |
| Zoellner, Y | 1 |
| Aronoff, GR | 1 |
| Safar, ME | 1 |
| Cuche, JL | 1 |
| Haag-Weber, M | 1 |
| Mai, B | 1 |
| Hörl, WH | 1 |
| Kierdorf, H | 1 |
| Müller, A | 1 |
| Blanke, PM | 1 |
| Gellert, J | 1 |
| Heintz, B | 1 |
| Rämsch, KD | 1 |
| Wargenau, M | 1 |
| Kindler, J | 1 |
| Manitius, J | 1 |
| Johns, EJ | 1 |
| Chamienia, AL | 1 |
| Schwenger, V | 1 |
| Zeier, M | 1 |
| Ritz, E | 1 |
| Mikoda, N | 1 |
| Nakagawa, H | 1 |
| Kawahara, K | 1 |
| Soons, PA | 1 |
| Ankermann, T | 2 |
| Breimer, DD | 1 |
| Kirch, W | 2 |
| Kloke, HJ | 2 |
| Wetzels, JF | 2 |
| van Hamersvelt, HW | 1 |
| Koene, RA | 2 |
| Kleinbloesem, CH | 2 |
| Huysmans, FT | 2 |
| Schiffl, H | 2 |
| Strasser, T | 1 |
| Ruilope, LM | 1 |
| Guerrero, L | 1 |
| Casal, MC | 1 |
| Alcazar, JM | 1 |
| Campo, C | 1 |
| Mazuecos, A | 1 |
| Fernandez, ML | 1 |
| Rodicio, JL | 1 |
| Boussac, I | 2 |
| Delavaux, G | 2 |
| Wight, JP | 1 |
| Brown, CB | 1 |
| el Nahas, AM | 1 |
| Mikus, G | 1 |
| Mast, V | 1 |
| Fischer, C | 1 |
| Machleidt, C | 1 |
| Kuhlmann, U | 1 |
| Eichelbaum, M | 1 |
| Jackson, B | 2 |
| Cubela, R | 1 |
| Debrevi, L | 1 |
| Whitty, M | 1 |
| Johnston, CI | 2 |
| Bambauer, R | 1 |
| Jutzler, GA | 1 |
| Weber, U | 1 |
| Walter, R | 1 |
| Keller, HE | 1 |
| Sluiter, HE | 1 |
| Weidmann, P | 2 |
| Schohn, D | 2 |
| Gnädinger, MP | 2 |
| Bürgisser, E | 1 |
| Ferrier, C | 1 |
| Jahn, H | 2 |
| Riesen, W | 1 |
| Osterkamp, U | 1 |
| Santos, SR | 1 |
| van Bortel, L | 1 |
| Böhm, R | 1 |
| Mooy, J | 1 |
| Schiffers, P | 1 |
| Rahn, KH | 2 |
| Herlitz, H | 1 |
| Nyberg, G | 1 |
| Granérus, G | 1 |
| Björck, S | 1 |
| Aurell, M | 1 |
| van Bortel, LM | 1 |
| Mooy, JM | 1 |
| Dal Canton, A | 1 |
| Esposito, C | 1 |
| Sabbatini, M | 1 |
| Altomonte, M | 1 |
| Romano, G | 1 |
| Veniero, P | 1 |
| Uccello, F | 1 |
| Andreucci, VE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Renal Denervation on Blood Pressure in Patients With Chronic Kidney Disease and Uncontrolled Hypertension[NCT04264403] | 44 participants (Actual) | Interventional | 2020-01-23 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 trials available for nitrendipine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients.
Topics: Adult; Antihypertensive Agents; Aortic Diseases; Arteriosclerosis; Atenolol; Blood Pressure; C-React | 2003 |
Moxonidine treatment of hypertensive patients with advanced renal failure.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Creatinine; Disease Progression; Female; Human | 2003 |
Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis.
Topics: Antihypertensive Agents; Cost-Benefit Analysis; Disease Progression; Humans; Hypertension, Renal; Im | 2007 |
Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aorta; Calcium Channel Blockers; Cardiomegaly; Compliance; | 1994 |
Effects of nitrendipine and cilazapril on renal hemodynamics and albuminuria in hypertensive patients with chronic renal failure.
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cilazapril; Doub | 1990 |
Hemodialysis-related leukotriene B4 generation and neutropenia during calcium channel blockade.
Topics: Aged; Aprotinin; Cellulose; Female; Humans; Kidney Failure, Chronic; Leukotriene B4; Male; Membranes | 1991 |
Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure.
Topics: Adult; Aged; Aging; Aortic Diseases; Arteriosclerosis; Blood Pressure; Calcinosis; Double-Blind Meth | 1991 |
Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure.
Topics: Administration, Oral; Aged; Analysis of Variance; Arteriosclerosis; Blood Pressure; Calcinosis; Doub | 1991 |
Antihypertensive effects of nitrendipine and cilazapril alone, and in combination in hypertensive patients with chronic renal failure.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Body Weight; Calcium Channel Blockers; Cilazapril; | 1989 |
Hypertensive dysregulation and its modification by calcium channel blockade in nonoliguric renal failure.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; Calcium Channel Blockers; Catecholamines; | 1989 |
Antihypertensive and hypouricaemic effects of nitrendipine in chronic renal failure.
Topics: Adult; Aged; Angiotensin II; Female; Humans; Hypertension; Kidney Failure, Chronic; Male; Middle Age | 1989 |
20 other studies available for nitrendipine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Nitrendipine and amlodipine mimic the acute effects of enalapril on renal haemodynamics and reduce glomerular hyperfiltration in patients with chronic kidney disease.
Topics: Adult; Amlodipine; Enalapril; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Kidney Failu | 2003 |
Pharmacokinetics of nitrendipine in patients with renal failure: comparison to normal subjects.
Topics: Adult; Aged; Biotransformation; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Crea | 1984 |
Normalization of enhanced neutrophil cytosolic free calcium of hemodialysis patients by 1,25-dihydroxyvitamin D3 or calcium channel blocker.
Topics: Blood Glucose; Calcitriol; Calcium; Calcium Channel Blockers; Humans; Kidney Failure, Chronic; Middl | 1993 |
Pharmacodynamics and pharmacokinetics of oral nitrendipine solution in hypertensive patients with advanced renal failure.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Female; Half-Life; Heart Rate; Humans; Hypertensi | 1993 |
The effect of nitrendipine on renal haemodynamics and tubular reabsorption and its neural control in anaesthetised rats with chronic renal failure.
Topics: Anesthesia; Animals; Calcium Channel Blockers; Hemodynamics; Homeostasis; Kidney Failure, Chronic; K | 1999 |
Antihypertensive therapy in renal patients - benefits and difficulties.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 1999 |
[Effects of nitrendipine on the development of hypertension and renal failure in Dahl salt-sensitive rats].
Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Glomerular Filtration Rate; Hypertension | 1999 |
Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function.
Topics: Administration, Oral; Aged; Female; Humans; Hypertension; Isomerism; Kidney Failure, Chronic; Male; | 1992 |
Tolerance to nitrendipine in patients with arterial hypertension accompanying chronic renal failure.
Topics: Adult; Analysis of Variance; Blood Pressure; Drug Tolerance; Female; Humans; Hypertension, Renal; Ki | 1991 |
Short-term effects of calcium antagonists on renal haemodynamics in patients with chronic renal failure.
Topics: Adolescent; Adult; Female; Hemodynamics; Humans; Kidney Failure, Chronic; Male; Middle Aged; Nifedip | 1991 |
Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension.
Topics: Adult; Aged; Biological Availability; Blood Pressure; Female; Humans; Hypertension; Kidney Failure, | 1991 |
Correlation of blood pressure in end-stage renal disease with platelet cytosolic free-calcium concentration.
Topics: Adult; Atenolol; Blood Platelets; Blood Pressure; Calcium; Cytosol; Female; Humans; Hypertension, Re | 1990 |
Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Diabetes Mellitus, Expe | 1987 |
Nitrendipine in patients with end-stage renal disease and hypertension.
Topics: Adult; Aged; Blood Pressure; Female; Heart Rate; Humans; Hypertension, Renal; Kidney Failure, Chroni | 1988 |
Elimination and haemodynamic effects of nitrendipine in patients with chronic renal failure.
Topics: Aged; Aged, 80 and over; Female; Hemodynamics; Humans; Kidney Failure, Chronic; Male; Middle Aged; N | 1989 |
Pharmacokinetics of nitrendipine in terminal renal failure.
Topics: Administration, Oral; Calcium Channel Blockers; Female; Humans; Infusions, Intravenous; Injections, | 1989 |
The contribution of systemic hypertension to progression of chronic renal failure in the rat remnant kidney: effect of treatment with an angiotensin converting enzyme inhibitor or a calcium inhibitor.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Calcium Channel Blockers; Enalapr | 1988 |
Effects of felodipine in patients with refractory hypertension and progressive renal disease.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Drug Ther | 1988 |
The use of calcium antagonists in patients with renal failure.
Topics: Calcium Channel Blockers; Diltiazem; Humans; Kidney Failure, Chronic; Nifedipine; Nitrendipine; Vera | 1987 |
Effects of nitrendipine in patients with chronic renal failure.
Topics: Adult; Aged; Blood Pressure; Female; Heart Rate; Humans; Kidney; Kidney Failure, Chronic; Male; Midd | 1986 |